An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

The blood test is designed to detect the accumulation of amyloid protein deposits in the brain, a hallmark of Alzheimer's disease.

An assessment of the documentation for 30 over-the-counter diagnostic tests found none met the current regulatory standards.

NEW YORK – Laboratory Corporation of America reported on Thursday morning that its second quarter revenues jumped almost 10 percent from a year ago, prompting the firm to raise its full-year revenue ...

Note: This story has been updated with comments from the company's conference call to discuss its financial results. NEW YORK – Despite volume-based procurement programs and healthcare pricing reforms ...

The test was developed in collaboration with Eli Lilly and can be used with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The cash deal includes ambulatory outreach laboratory services in 13 states and includes patient service centers and in-office phlebotomy sites.